Ethical reflections on clinical trials with human tissue engineered products

Area of Science:

• Biomedical Engineering
• Regenerative Medicine
• Clinical Ethics

Background:

• Ex-vivo tissue engineering aims to regenerate tissues and organs for full physiological function.
• Clinical trials involving human tissue-engineered products (HTEPs) are increasing, necessitating rigorous evaluation.
• The inherent complexity of tissue engineering processes and products poses unique challenges for clinical trial design and ethical oversight.

Purpose of the Study:

• To investigate the ethical implications of complexity in clinical trials for HTEPs.
• To examine how complexity impacts trial validity, risk-benefit assessment, and participant protection.
• To propose a framework for ethically sound clinical trials involving HTEPs.

Main Methods:

• Analysis of ethical considerations in HTEP clinical trials.
• Focus on trial value, validity, risk-benefit ratio, and participant safety.
• Review of challenges in informed consent for complex regenerative medicine products.

Main Results:

• Complexities in HTEP development necessitate robust trial methodologies.
• Accurate determination and comparison of risk-benefit ratios are essential.
• Tissue engineering complexity significantly challenges informed consent and long-term participant protection.

Conclusions:

• Ethical conduct of HTEP trials demands rigorous methodology and risk minimization.
• A thorough risk-benefit analysis, benchmarked against existing therapies, is imperative.
• Enhanced informed consent processes and participant safeguards are critical for complex tissue engineering trials.